share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4：持股變動聲明-高管 Kulkarni Samarth
美股sec公告 ·  04/18 05:50
牛牛AI助理已提取核心訊息
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on April 15, 2024, involving the sale of company shares. Kulkarni sold a total of 19,582 shares of common stock at prices ranging from $59.8819 to $60.4003, resulting in a total market value of approximately $1,173,231.52. Prior to the sales, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on April 15, 2024, involving the sale of company shares. Kulkarni sold a total of 19,582 shares of common stock at prices ranging from $59.8819 to $60.4003, resulting in a total market value of approximately $1,173,231.52. Prior to the sales, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 208,122 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼於2024年4月15日完成了一筆涉及出售公司股票的股票交易。庫爾卡尼共出售了19,582股普通股，價格從59.8819美元到60.4003美元不等，總市值約爲1,173,231.52美元。在出售之前，庫爾卡尼行使了期權，以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼直接持有CRISPR Therapeutics的208,122股股份。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。
CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼於2024年4月15日完成了一筆涉及出售公司股票的股票交易。庫爾卡尼共出售了19,582股普通股，價格從59.8819美元到60.4003美元不等，總市值約爲1,173,231.52美元。在出售之前，庫爾卡尼行使了期權，以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼直接持有CRISPR Therapeutics的208,122股股份。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。